Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver
Tweet Send to a Friend
Roth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
